Please wait while we open this resource.
K
Clinical reviews
TUCIDINOSTAT PLUS R-CHOP VS R-CHOP IN MYC/BCL2 DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA
Hematology
PDF2 pages189 KB
MYC/BCL2 double-expressor lymphoma is a subtype of diffuse large B-cell lymphoma (DLBCL), marked by poor response to standard immunochemotherapy. This study involved 423 patients and was a randomized, double-blind, placebo-controlled, phase 3 clinical trial. The findings suggest that tucidinostat added to R-CHOP may improve event-free survival and complete response rates, although it also showed increased toxicity. Limitations include the study's single ethnic population and the need for further evaluation of maintenance tucidinostat.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Myeloproliferative Neoplasms
Same clinical topic · Hematology
MASTOCYTOSIS
Same clinical topic · Hematology
MYELODYSPLASTIC SYNDROMES: 2023 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT
Same clinical topic · Hematology
PERIPHERAL T-CELL LYMPHOMAS
Same clinical topic · Hematology
COMPARISON OF THE INTERNATIONAL CONSENSUS AND 5TH WHO EDITION CLASSIFICATIONS OF ADULT MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Same clinical topic · Hematology
VEXAS SYNDROME: A COMPREHENSIVE REVIEW OF PATHOGENESIS, CLINICAL SPECTRUM, AND THERAPEUTIC STRATEGIES
Same clinical topic · Hematology
IRON DEFICIENCY
Same clinical topic · Hematology
MULTIPLE MYELOMA: 2026 UPDATE ON DIAGNOSIS, RISK-STRATIFICATION AND MANAGEMENT
Same clinical topic · Hematology
ANTIDOTES FOR ANTICOAGULATION REVERSAL
Same clinical topic · Hematology